OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
| Autor: | Walter Reinisch, K Farkas, H N Kim, Byong Duk Ye, Shomron Ben-Horin, A Pukitis, S H Kim, R Dudkowiak, Stefan Schreiber, Marek Horynski, B Gawdis-Wojnarska, M Kowalski, Jaroslaw Kierkus, Y A Kim, Adi Lahat, J Leszczyszyn, S J Lee, M R Kim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Crohn's disease
medicine.medical_specialty Randomization business.industry Gastroenterology Mucous membrane General Medicine medicine.disease Crohn's Disease Activity Index Ulcerative colitis Infliximab medicine.anatomical_structure Rheumatoid arthritis Internal medicine medicine In patient business medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 14:S021-S022 |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjz203.023 |
| Popis: | Background Two randomised controlled trials of a novel subcutaneous (SC) formulation of infliximab in patients with active rheumatoid arthritis1 and in patients with active Crohn’s disease (CD) and ulcerative colitis (UC)2 confirmed comparable clinical efficacy and safety of CT-P13 SC with CT-P13 intravenous (IV) up to Week 30. We now present the efficacy, pharmacokinetics (PK) and safety of CT-P13 SC over 1-year in the active CD and UC trial, including the outcomes of switching from CT-P13 IV to CT-P13 SC. Methods After loading doses of IV 5 mg/kg at Weeks 0 and 2, patients were randomised at Week 6 to receive either SC 120 mg ( Results A total of 131 patients were randomised (66 to the SC arm and 65 to the IV arm); of whom, 105 (80.2%) patients completed the Week 54 visit (55 in the SC arm and 50 in the IV arm). The mean CDAI and partial Mayo scores decreased over time in the 2 arms until Week 30 and comparable improvement in clinical activity was observed at Week 54 after switching the remaining IV patients to SC (Figure 1 and 2). The rates of clinical response and remission were also maintained at Week 54 and the rate of mucosal healing in combined CD and UC was further improved at Week 54 (Table 1). The mean pre-dose serum concentrations in the IV arm increased to a similar level to SC arm after switching and maintained consistent levels until Week 54 (Figure 3). The safety profiles during the maintenance phase and on or after Week 30 were generally comparable between the 2 arms (Table 1). All of the localised injection site reactions were grade 1 or 2 in intensity and majority of patients recovered without any treatments. Conclusion These results of CT-P13 SC 1-year study in active CD and UC show comparable efficacy and safety of the SC and IV formulations, which were not affected by a switch of IV patients to SC route. The PK as manifested by trough concentrations of the drug, increased after switching from IV to SC. These observations support the first infliximab SC formulation as a viable therapeutic agent to expand patients’ treatment options. References |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|